New York to Add Terpene Testing As a Requirement For Medical Cannabis Labs
Image credit: iStock
New York’s Cannabis Control Board (CCB) has voted to update the state’s cannabis testing regulations, including a requirement to report terpene content for medical cannabis products.
The new rule is one of many the CCB recently approved in an effort to “swiftly grow the state’s legal cannabis market”.
In a notice published on July 19, the CCB and Office of Cannabis Management announced that they had approved the state’s Cannabis Growers’ Showcase initiative, a cannabis events program that would allow the first legal in-person recreational cannabis sales outside the walls of a dispensary.
The regulators also approved emergency measures to institute a minimum ratio of CBD to THC for all cannabinoid hemp products and a maximum amount of total THC for certain hemp products.
The revisions prohibit the sale of cannabinoid hemp products with over 0.5 milligrams of total THC per serving to individuals under 21.
“These changes will help ensure that intoxicating cannabinoid hemp products are not sold in the cannabinoid hemp program where the regulations differ in the provisions and safeguards that exist in the adult-use program,” the CCB wrote in its announcement.
The regulator also voted to adopt new rules that would affect those licensed to research the cannabis plant in the state of New York.
“These licenses will help further research into cannabis, a space of research that has been severely limited by a century of cannabis prohibition in the United States,” the CCB wrote.
One additional cannabis lab license was also announced – awarded to Coral Reef Labs in Johnson City – bringing the total number of licensed cannabis labs in the state to 15.
